<!doctype html><html class=no-js lang=en><head><meta charset=UTF-8><meta name=viewport content="width=device-width,initial-scale=1"><title>ç§‘ç ”æ—¥æŠ¥ 2025-12-17 - ç”Ÿä¿¡æ™®æ‹‰æ–¯</title>
<script>(function(e,t){e[t]=e[t].replace("no-js","js")})(document.documentElement,"className")</script><meta name=description content><meta property="og:url" content="https://ixxmu.github.io/posts/dailyreports/2025-12-17/"><meta property="og:site_name" content="ç”Ÿä¿¡æ™®æ‹‰æ–¯"><meta property="og:title" content="ç§‘ç ”æ—¥æŠ¥ 2025-12-17"><meta property="og:description" content="ğŸ“… Daily Report - 2025-12-17 ä»Šæ—¥ç­›é€‰å‡º 72 æ¡å†…å®¹ï¼Œæ¥è‡ª 2 ä¸ªæ¥æº"><meta property="og:locale" content="zh_cn"><meta property="og:type" content="article"><meta property="article:section" content="posts"><meta property="article:published_time" content="2025-12-17T00:00:00+00:00"><meta property="article:modified_time" content="2025-12-17T00:00:00+00:00"><meta property="article:tag" content="Research"><meta property="article:tag" content="Daily"><meta property="article:tag" content="Week512025"><meta itemprop=name content="ç§‘ç ”æ—¥æŠ¥ 2025-12-17"><meta itemprop=description content="ğŸ“… Daily Report - 2025-12-17 ä»Šæ—¥ç­›é€‰å‡º 72 æ¡å†…å®¹ï¼Œæ¥è‡ª 2 ä¸ªæ¥æº"><meta itemprop=datePublished content="2025-12-17T00:00:00+00:00"><meta itemprop=dateModified content="2025-12-17T00:00:00+00:00"><meta itemprop=wordCount content="2141"><meta itemprop=keywords content="Research,Daily,Week512025"><meta name=twitter:card content="summary"><meta name=twitter:title content="ç§‘ç ”æ—¥æŠ¥ 2025-12-17"><meta name=twitter:description content="ğŸ“… Daily Report - 2025-12-17 ä»Šæ—¥ç­›é€‰å‡º 72 æ¡å†…å®¹ï¼Œæ¥è‡ª 2 ä¸ªæ¥æº"><link rel=preconnect href=https://fonts.gstatic.com crossorigin><link rel=dns-prefetch href=//fonts.googleapis.com><link rel=dns-prefetch href=//fonts.gstatic.com><link rel=stylesheet href="https://fonts.googleapis.com/css?family=Open+Sans:400,400i,700"><link rel=stylesheet href=../../../css/style.css><link rel=stylesheet href=../../../css/custom.css><link rel="shortcut icon" href=../../../favicon.ico></head><body class=body><div class="container container--outer"><header class=header><div class="container header__container"><div class=logo><a class=logo__link href=../../../ title=ç”Ÿä¿¡æ™®æ‹‰æ–¯ rel=home><div class="logo__item logo__text"><div class=logo__title>ç”Ÿä¿¡æ™®æ‹‰æ–¯</div><div class=logo__tagline>è¿‘åå¹´æœ€å€¼å¾—ä¸Šæ‰‹çš„ç”Ÿç‰©åŒ»å­¦ç”Ÿä¿¡ä»£ç </div></div></a></div><nav class=menu><button class=menu__btn aria-haspopup=true aria-expanded=false tabindex=0>
<span class=menu__btn-title tabindex=-1>Menu</span></button><ul class=menu__list><li class=menu__item><a class=menu__link href=../../../posts/><span class=menu__text>æ–‡ç« </span></a></li><li class=menu__item><a class=menu__link href=../../../tags/><span class=menu__text>æ ‡ç­¾</span></a></li><li class=menu__item><a class=menu__link href=../../../about/><span class=menu__text>å…³äº</span></a></li></ul></nav></div></header><div class="wrapper flex"><div class=primary><main class=main role=main><article class=post><header class=post__header><meta name=referrer content="never"><h1 class=post__title>ç§‘ç ”æ—¥æŠ¥ 2025-12-17</h1><div class="post__meta meta"><div class="meta__item-datetime meta__item"><svg class="meta__icon icon icon-time" width="16" height="14" viewBox="0 0 30 28"><path d="M15 0a14 14 0 110 28 1 1 0 010-28m0 3a3 3 0 100 22 3 3 0 000-22m1 4h-2v8.4l6.8 4.4L22 18l-6-3.8z"/></svg><time class=meta__text datetime=2025-12-17T00:00:00Z>2025-12-17</time></div><div class="meta__item-categories meta__item"><svg class="meta__icon icon icon-category" width="16" height="16" viewBox="0 0 16 16"><path d="m7 2 1 2h8v11H0V2z"/></svg><span class=meta__text><a class=meta__link href=../../../categories/dailyreport/ rel=category>DailyReport</a></span></div><div class="meta__item-author meta__item"><svg class="meta__icon icon icon-author" width="16" height="16" viewBox="0 0 16 16"><path d="M8 1c2 0 3.5 2 3.5 4.5S10 9 10 9c3 1 4 2 4 6H2c0-4 1-5 4-6 0 0-1.5-1-1.5-3.5S6 1 8 1"/></svg><span class=meta__text>Bloger</span></div></div></header><div class="post__toc toc"><div class=toc__title>Page content</div><div class=toc__menu><nav id=TableOfContents><ul><li><a href=#-ä»Šæ—¥aiæ™ºèƒ½æ€»ç»“>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</a><ul><li><a href=#-æ•°æ®å‰æ²¿>ğŸ§¬ æ•°æ®å‰æ²¿</a></li><li><a href=#-åšå®¢æ›´æ–°>ğŸ§ª åšå®¢æ›´æ–°</a></li></ul></li><li><a href=#-åˆ†ç±»æµè§ˆ>ğŸ“š åˆ†ç±»æµè§ˆ</a><ul><li></li></ul></li><li><a href=#-å…³é”®è¯ç»Ÿè®¡>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</a></li><li><a href=#-æ›´å¤šå†…å®¹>ğŸ“ æ›´å¤šå†…å®¹</a></li></ul></nav></div></div><div class="content post__content clearfix"><h1 id=-daily-report---2025-12-17>ğŸ“… Daily Report - 2025-12-17</h1><blockquote><p>ä»Šæ—¥ç­›é€‰å‡º <strong>72</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>2</strong> ä¸ªæ¥æº</p></blockquote><div class=powered-by-top>Powered by <a href=https://kyplus.de>ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href=https://claude.ai>Claude</a></div><hr><h2 id=-ä»Šæ—¥aiæ™ºèƒ½æ€»ç»“>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2><h3 id=-æ•°æ®å‰æ²¿>ğŸ§¬ æ•°æ®å‰æ²¿</h3><blockquote><p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š
ADAM12è¢«é‰´å®šä¸ºé˜»ç¢è‚¿ç˜¤å…ç–«çš„å…³é”®æ€§æˆçº¤ç»´ç»†èƒæ£€æŸ¥ç‚¹ï¼›EWSR1::ETSç™ŒåŸºå› é€šè¿‡è°ƒæ§æ ¸å¿ƒè°ƒæ§ç¯è·¯æœºåˆ¶åœ¨å°¤æ–‡æ°è‚‰ç˜¤ä¸­å‘æŒ¥ä¸»å¯¼ä½œç”¨ã€‚</p></blockquote><p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š</p><ul><li>è‚ é“é»è†œå…ç–«ï¼šç ”ç©¶PKM2/STAT1é€šè·¯åœ¨Peyer&rsquo;sé›†åˆæ·‹å·´ç»“ä¸­å¯¹å¹¼ç¨šBç»†èƒå‘½è¿çš„å½±å“ã€‚</li><li>è‚¿ç˜¤å…ç–«ï¼šæ¢ç©¶ADAM12åœ¨ä¸åŒè‚¿ç˜¤æ¨¡å‹ä¸­ä½œä¸ºæˆçº¤ç»´ç»†èƒæ£€æŸ¥ç‚¹é˜»ç¢æŠ—è‚¿ç˜¤å…ç–«çš„æœºåˆ¶ã€‚</li><li>å°¤æ–‡æ°è‚‰ç˜¤ï¼šè§£æEWSR1::ETSç™ŒåŸºå› å¦‚ä½•é‡å¡‘å…¶æ ¸å¿ƒè°ƒæ§ç¯è·¯ã€‚</li><li>è„‚è´¨æ°§åŒ–è‡ªç”±åŸºé˜²å¾¡ï¼šæ­ç¤ºäº†å…¶ä¿¡å·é€šè·¯å’Œè¡¨è§‚é—ä¼ è°ƒæ§æœºåˆ¶ã€‚</li><li>m6Aè¡¨è§‚è½¬å½•ç»„ç¼–è¾‘ï¼šç­›é€‰å¹¶é‰´å®šç™Œç—‡ä¸­çš„åŠŸèƒ½æ€§m6Aä½ç‚¹ã€‚</li></ul><p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š</p><ul><li>å•ç»†èƒæµ‹åºï¼ˆscRNA-seqï¼‰æŠ€æœ¯åœ¨è‚¿ç˜¤å…ç–«å’Œç¥ç»ç§‘å­¦ä¸­çš„å¹¿æ³›åº”ç”¨ã€‚</li><li>Connectome-seqï¼šå®ç°å•çªè§¦åˆ†è¾¨ç‡ç¥ç»å…ƒè¿æ¥å›¾è°±ç»˜åˆ¶ã€‚</li></ul><h3 id=-åšå®¢æ›´æ–°>ğŸ§ª åšå®¢æ›´æ–°</h3><blockquote><p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š
ç ”ç©¶äººå‘˜å› åœ¨åŸºå› ç»„ä¸RNAæµ‹åºæŠ€æœ¯ä¸Šçš„çªç ´æ€§åº”ç”¨ï¼Œæ˜¾è‘—æå‡äº†ç½•è§ç—…è¯Šæ–­èƒ½åŠ›ï¼›åŒæ—¶ï¼Œå¤§éº»åŒ–åˆç‰©ï¼ˆCBDä¸THCï¼‰å¯¹åµå·¢ç™Œç»†èƒå±•ç°å‡ºå¼ºæ•ˆæŠ‘åˆ¶ä½œç”¨ï¼Œä¸ºç™Œç—‡æ²»ç–—å¸¦æ¥æ–°å¸Œæœ›ã€‚</p></blockquote><p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š</p><ul><li>åˆ©ç”¨RNAæµ‹åºä¸å› æœå»ºæ¨¡ï¼Œè§£æåŸºå› é€šè·¯ä¸äººç±»æ€§çŠ¶çš„è”ç³»ã€‚</li><li>æ¢ç´¢å¤§éº»åŒ–åˆç‰©ï¼ˆCBDã€THCï¼‰åœ¨æŠ‘åˆ¶åµå·¢ç™Œç»†èƒç”Ÿé•¿å’Œè½¬ç§»ä¸­çš„æ½œåŠ›ã€‚</li><li>è¯„ä¼°ç„¦è™‘å’Œå¤±çœ å¯¹å…ç–«ç»†èƒï¼ˆç‰¹åˆ«æ˜¯è‡ªç„¶æ€ä¼¤ç»†èƒï¼‰æ•°é‡çš„å½±å“ã€‚</li></ul><p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š</p><ul><li>æ•´åˆåŸºå› æ•ˆåº”å¤§å°ä¸RNAæµ‹åºæ‰°åŠ¨æ•°æ®ï¼Œæ„å»ºåŸºå› è‡³ç»†èƒç¨‹åºåŠäººç±»æ€§çŠ¶çš„å› æœé€šè·¯å›¾ã€‚</li><li>å‘ç°CBDä¸THCè”åˆä½¿ç”¨èƒ½æœ‰æ•ˆå‡ç¼“åµå·¢ç™Œç»†èƒç”Ÿé•¿å’Œé›†è½å½¢æˆã€‚</li></ul><hr><h2 id=-åˆ†ç±»æµè§ˆ>ğŸ“š åˆ†ç±»æµè§ˆ</h2><details><summary style="text-align:right;direction:rtl;padding:10px 15px;background:linear-gradient(135deg,#f8f9fa 0%,#e9ecef 100%);border-right:4px solid #667eea;font-weight:600;cursor:pointer;margin:15px 0;border-radius:6px">ğŸ§¬ æ•°æ®å‰æ²¿ (68æ¡)</summary><div class=details-content markdown=1><h4 id=è¯¦ç»†å†…å®¹å‰10æ¡>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4><p><strong>1.</strong> â­ <strong>GSE285427 PKM2/STAT1é€šè·¯è°ƒæ§æ´¾æ°æ·‹å·´é›†ç»“å†…ç”Ÿå‘ä¸­å¿ƒå½¢æˆä¸­å¹¼ç¨šBç»†èƒçš„å‘½è¿ä»¥åŠè‚ é“é»è†œå…ç–«</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmunityã€B cellã€pathwayã€gutã€regex:gut(-?microbiome)?</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Li Zeng ; Zhiyin HuangSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusThis study investigates the effects of high-protein diets on intestinal B cell development and their role in Crohnâ€™s disease (CD) pathogenesis. Our results demonstrate that a high-protein diet (HPD) combined with low-dose dextran sulfate sodium (DSS) effectively models CD in juvenile mice, leading to disrupted B cell development in Peyerâ€™s patches (PPs). This is characterized by a reduction in germinal center (GC) B cells and an increase in plasma cells in PPs, accompanied by downregulation of the PKM2/STAT1 signaling pathway in B cells, as validated through single-cell RNA sequencing (scRNA-seq), BCR sequencing (scBCR-seq) and flow cytometry.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285427">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>2.</strong> â­ <strong>GSE313761 å•ç»†èƒç­›é€‰é‰´å®šå‡º ADAM12 ä¸ºæˆçº¤ç»´ç»†èƒæ£€æŸ¥ç‚¹ï¼Œé˜»ç¢æŠ—è‚¿ç˜¤å…ç–«â€”â€”Adam12CKO å°é¼ æ¨¡å‹ CD45- ç»†èƒçš„ scRNA-seq</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€immunityã€single-cellã€scRNA</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusClinical trials targeting cancer-associated fibroblasts (CAFs)â€”crucial pro-tumoral factors in cancerâ€”have almost all failed. This may be ascribed to their intrinsic functional plasticity and the opaque regulatory circuits underlying their heterogeneous phenotypes within tumors. We address these by developing a systematic screening approach for patient-derived fibroblasts using complementary CRISPR interference (CRISPRi) and activation (CRISPRa)-based perturb-seq. An anti-tumoral interferon (IFN)-I response-associated program is identified as the primary antagonism axis counteracting TGFÎ²-driven pro-tumoral myofibroblast activation. ADAM12 emerges as a molecular checkpoint mediating this relationship. Its ablation elicits IFN-I responsive programs, reconfigures myofibroblast population structures into progenitor-like states, revitalizes T cell-based immune responses, and induces tumor rejection across various murine models. Further combined with human genomics data analysis, our findings position ADAM12 as a potential target for fibroblasts, paving the way for actionable therapeutic interventions.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313761">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>3.</strong> â­ <strong>GSE278983 å•ç»†èƒç­›é€‰é‰´å®šå‡ºADAM12ä¸ºæˆçº¤ç»´ç»†èƒæ£€æŸ¥ç‚¹ï¼Œé˜»ç¢æŠ—è‚¿ç˜¤å…ç–«â€”â€”å°é¼ KPCæ¨¡å‹çš„scRNA-seq</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€immunityã€single-cellã€scRNA</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusClinical trials targeting cancer-associated fibroblasts (CAFs)â€”crucial pro-tumoral factors in cancerâ€”have almost all failed. This may be ascribed to their intrinsic functional plasticity and the opaque regulatory circuits underlying their heterogeneous phenotypes within tumors. We address these by developing a systematic screening approach for patient-derived fibroblasts using complementary CRISPR interference (CRISPRi) and activation (CRISPRa)-based Perturb-seq . An anti-tumoral interferon (IFN)-I response-associated program is identified as the primary antagonism axis counteracting TGFÎ²-driven pro-tumoral myofibroblast activation. ADAM12 emerges as a molecular checkpoint mediating this relationship. Its ablation elicits IFN-I responsive programs, reconfigures myofibroblast population structures into progenitor-like states, revitalizes T cell-based immune responses, and induces tumor rejection across various murine models. Further combined with human genomics data analysis, our findings position ADAM12 as a potential target for fibroblasts, paving the way for actionable therapeutic interventions.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE278983">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>4.</strong> â­ <strong>GSE278980 å•ç»†èƒç­›é€‰é‰´å®šå‡º ADAM12 ä¸ºæˆçº¤ç»´ç»†èƒæ£€æŸ¥ç‚¹ï¼Œé˜»ç¢æŠ—è‚¿ç˜¤å…ç–«â€”â€”C57BL/6 å°é¼ æ¨¡å‹çš„ RNA æµ‹åº</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€immunityã€RNA-seqã€single-cell</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusClinical trials targeting cancer-associated fibroblasts (CAFs)â€”crucial pro-tumoral factors in cancerâ€”have almost all failed. This may be ascribed to their intrinsic functional plasticity and the opaque regulatory circuits underlying their heterogeneous phenotypes within tumors. We address these by developing a systematic screening approach for patient-derived fibroblasts using complementary CRISPR interference (CRISPRi) and activation (CRISPRa)-based Perturb-seq . An anti-tumoral interferon (IFN)-I response-associated program is identified as the primary antagonism axis counteracting TGFÎ²-driven pro-tumoral myofibroblast activation. ADAM12 emerges as a molecular checkpoint mediating this relationship. Its ablation elicits IFN-I responsive programs, reconfigures myofibroblast population structures into progenitor-like states, revitalizes T cell-based immune responses, and induces tumor rejection across various murine models. Further combined with human genomics data analysis, our findings position ADAM12 as a potential target for fibroblasts, paving the way for actionable therapeutic interventions.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE278980">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>5.</strong> â­ <strong>GSE278975 å•ç»†èƒç­›é€‰é‰´å®šå‡ºADAM12æ˜¯æˆçº¤ç»´ç»†èƒæ£€æŸ¥ç‚¹ï¼Œå¯é˜»ç¢æŠ—è‚¿ç˜¤å…ç–«â€”â€”å…±æ³¨å°„å°é¼ æ¨¡å‹çš„scRNA-seq</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€immunityã€single-cellã€scRNA</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusClinical trials targeting cancer-associated fibroblasts (CAFs)â€”crucial pro-tumoral factors in cancerâ€”have almost all failed. This may be ascribed to their intrinsic functional plasticity and the opaque regulatory circuits underlying their heterogeneous phenotypes within tumors. We address these by developing a systematic screening approach for patient-derived fibroblasts using complementary CRISPR interference (CRISPRi) and activation (CRISPRa)-based Perturb-seq . An anti-tumoral interferon (IFN)-I response-associated program is identified as the primary antagonism axis counteracting TGFÎ²-driven pro-tumoral myofibroblast activation. ADAM12 emerges as a molecular checkpoint mediating this relationship. Its ablation elicits IFN-I responsive programs, reconfigures myofibroblast population structures into progenitor-like states, revitalizes T cell-based immune responses, and induces tumor rejection across various murine models. Further combined with human genomics data analysis, our findings position ADAM12 as a potential target for fibroblasts, paving the way for actionable therapeutic interventions.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE278975">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>6.</strong> â­ <strong>GSE278974 å•ç»†èƒç­›é€‰é‰´å®šå‡º ADAM12 ä¸ºæˆçº¤ç»´ç»†èƒæ£€æŸ¥ç‚¹ï¼Œé˜»ç¢æŠ—è‚¿ç˜¤å…ç–«â€”â€”B16F10 è‚ºé»‘è‰²ç´ ç˜¤å°é¼ æ¨¡å‹çš„ RNA-seq</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€immunityã€RNA-seqã€single-cell</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusClinical trials targeting cancer-associated fibroblasts (CAFs)â€”crucial pro-tumoral factors in cancerâ€”have almost all failed. This may be ascribed to their intrinsic functional plasticity and the opaque regulatory circuits underlying their heterogeneous phenotypes within tumors. We address these by developing a systematic screening approach for patient-derived fibroblasts using complementary CRISPR interference (CRISPRi) and activation (CRISPRa)-based Perturb-seq . An anti-tumoral interferon (IFN)-I response-associated program is identified as the primary antagonism axis counteracting TGFÎ²-driven pro-tumoral myofibroblast activation. ADAM12 emerges as a molecular checkpoint mediating this relationship. Its ablation elicits IFN-I responsive programs, reconfigures myofibroblast population structures into progenitor-like states, revitalizes T cell-based immune responses, and induces tumor rejection across various murine models. Further combined with human genomics data analysis, our findings position ADAM12 as a potential target for fibroblasts, paving the way for actionable therapeutic interventions.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE278974">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>7.</strong> â­ <strong>GSE311439 è„‚è´¨æ°§è‡ªç”±åŸºé˜²å¾¡é€šè·¯åŠå…¶è¡¨è§‚é—ä¼ æ§åˆ¶çš„é‰´å®š [ChIP-Seq]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šChIP-seqã€epigeneticã€pathway</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Francisco S Mesquita ; Laurence Abrami ; Romain Forey ; BÃ©atrice Kunz ; CharlÃ¨ne Raclot ; Lucie Bracq ; Danica Milovanovic ; Evarist Planet ; Olga Rosspopoff ; Filipe Martins ; Didier Trono ; Gisou van der GootSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensMembrane phospholipids are vulnerable to oxidative radicals, and uncontrolled lipid peroxidation affects cell viability. Cells have evolved quality control and defense mechanisms, of which the genetic regulation is not fully understood. Here, we identify what we have coined the Lipid Oxygen Radical Defense (LORD) pathway. It is epigenetically repressed by a complex comprising the KRAB-zinc finger protein ZNF354A, the scaffold protein KAP1/TRIM28, the histone methyltransferase SETDB1, and the transcriptional activator ATF2. Upon lipid peroxide accumulation, p38- and JNK-dependent phosphorylation of ATF2, KAP1/TRIM28, and ZNF354A leads to disassembly of the repressive complex, releasing ZNF354A from specific DNA loci and activating a network of protective genes, including NRF2 targets. The pathway affects the cellular sensitivity to oxidative stress and ferroptosis, revealing a previously uncharacterized layer of epigenetic control in lipid quality control and damage repair. This positions the LORD pathway as a promising therapeutic target for diseases linked to chronic inflammation, neurodegeneration and cancer.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311439">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>8.</strong> â­ <strong>GSE311436 è„‚è´¨æ°§è‡ªç”±åŸºé˜²å¾¡é€šè·¯åŠå…¶è¡¨è§‚é—ä¼ æ§åˆ¶çš„é‰´å®š [RNA-Seq]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šRNA-seqã€epigeneticã€pathway</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Francisco S Mesquita ; Evarist Planet ; Laurence Abrami ; Charlene Raclot ; Romain Forey ; Gisou van der GootSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensMembrane phospholipids are vulnerable to oxidative radicals, and uncontrolled lipid peroxidation affects cell viability. Cells have evolved quality control and defense mechanisms, of which the genetic regulation is not fully understood. Here, we identify what we have coined the Lipid Oxygen Radical Defense (LORD) pathway. It is epigenetically repressed by a complex comprising the KRAB-zinc finger protein ZNF354A, the scaffold protein KAP1/TRIM28, the histone methyltransferase SETDB1, and the transcriptional activator ATF2. Upon lipid peroxide accumulation, p38- and JNK-dependent phosphorylation of ATF2, KAP1/TRIM28, and ZNF354A leads to disassembly of the repressive complex, releasing ZNF354A from specific DNA loci and activating a network of protective genes, including NRF2 targets. The pathway affects the cellular sensitivity to oxidative stress and ferroptosis, revealing a previously uncharacterized layer of epigenetic control in lipid quality control and damage repair. This positions the LORD pathway as a promising therapeutic target for diseases linked to chronic inflammation, neurodegeneration and cancer.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311436">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>9.</strong> â­ <strong>GSE278990 å•ç»†èƒç­›é€‰å‘ç° ADAM12 æ˜¯æˆçº¤ç»´ç»†èƒæ£€æŸ¥ç‚¹ï¼Œå¯é˜»ç¢æŠ—è‚¿ç˜¤å…ç–«</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€immunityã€single-cell</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusThis SuperSeries is composed of the SubSeries listed below.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE278990">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>10.</strong> <strong>GSE293631 éœ¸æƒ EWSR1::ETS ç™ŒåŸºå› åœ¨å°¤æ–‡æ°è‚‰ç˜¤ä¸­å‡Œé©¾äºæ ¸å¿ƒè°ƒæ§å›è·¯æœºåˆ¶ä¹‹ä¸Š [ChIP-seq 2]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šregex:onco(logy|logist|gene|genic)ã€ChIP-seq</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Sandrine Grossetete ; Sakina Zaidi ; Karine Laud-Duval ; Didier Surdez ; Olivier DelattreSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensEwing sarcoma is an aggressive bone tumor of adolescence characterized by a hallmark EWSR1::FLI1 fusion oncogene. This chimeric protein drives tumorigenesis by reshaping transcriptional and epigenetic landscapes. However, how it is transcriptionally regulated and whether additional master transcription factors (MTFs) form a core regulatory circuit (CRC) in Ewing sarcoma remain unclear. Here, using an extensive panel of Ewing sarcoma cell lines and primary tumors, we mapped super-enhancers and identified strong enrichment of GGAA microsatellites, confirming their specificity to Ewing sarcoma as compared to other pediatric cancers and normal tissues. Integrating transcriptomic, epigenetic, 3D chromatin conformation, and dependency data, we predicted a set of MTFs potentially comprising a CRC. However, functional validation demonstrated that these MTFs neither establish auto-regulatory loops nor confer proliferative dependencies typical of CRC s in other pediatric tumors. Instead, EWSR1::FLI1 emerged as an â€œhegemonicâ€ oncogene, regulating the expression of these MTFs without reciprocal regulation. Knockdown (KD) of EWSR1::FLI1 strongly reduced Ewing sarcoma cell proliferation and shifted H3K27ac profiles toward mesenchymal states, whereas silencing of individual or combined MTFs did not alter cell growth or EWSR1::FLI1 expression. These findings highlight the absence of a classical CRC in Ewing sarcoma and emphasize EWSR1::FLI1 as the dominant oncogene but also as a major vulnerability in this disease.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293631">æŸ¥çœ‹åŸæ–‡</a></li></ul><blockquote><p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 58 æ¡å†…å®¹ï¼Œè¯¦è§ <a href=#%E6%9B%B4%E5%A4%9A-%E6%95%B0%E6%8D%AE%E5%89%8D%E6%B2%BF>æ–‡æœ«</a></p></blockquote></div></details><details><summary style="text-align:right;direction:rtl;padding:10px 15px;background:linear-gradient(135deg,#f8f9fa 0%,#e9ecef 100%);border-right:4px solid #667eea;font-weight:600;cursor:pointer;margin:15px 0;border-radius:6px">ğŸ§ª åšå®¢æ›´æ–° (4æ¡)</summary><div class=details-content markdown=1><h4 id=è¯¦ç»†å†…å®¹å…¨éƒ¨4æ¡>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨4æ¡ï¼‰</h4><p><strong>1.</strong> <strong>ç ”ç©¶äººå‘˜å› åŸºå› ç»„å’ŒRNAæµ‹åºçš„å˜é©æ€§åº”ç”¨è€Œè·å¥–</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsequencingã€genome</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šPengfei Liu, Ph.D., is recognized for advancing RNA sequencing and genome-based diagnostics, improving rare disease diagnosis&mldr;</li><li>ğŸ”— <a href=https://www.rna-seqblog.com/researcher-awarded-for-transformative-use-of-genome-and-rna-sequencing/>æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>2.</strong> <strong>åˆ©ç”¨RNAæµ‹åºå’Œå› æœæ¨¡å‹å°†åŸºå› ä¸æ€§çŠ¶è”ç³»èµ·æ¥</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsequencing</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šBy combining genetic effect sizes with RNA sequencing based perturbation data, researchers map causal pathways from genes to cellular programs and human traits&mldr;</li><li>ğŸ”— <a href=https://www.rna-seqblog.com/linking-genes-to-traits-using-rna-sequencing-and-causal-modeling/>æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>3.</strong> <strong>å¤§éº»åŒ–åˆç‰©å±•ç°å‡ºå¯¹æŠ—åµå·¢ç™Œçš„æ„å¤–åŠŸæ•ˆ</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancer</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šScientists have discovered that key compounds from cannabisâ€”CBD and THCâ€”show surprisingly strong effects against ovarian cancer cells. Used together, they slow cell growth, reduce colony formation, and may even block the cancerâ€™s ability to spread. Even more promising, the treatment caused minimal harm to healthy cells and appears to work by restoring a disrupted signaling pathway that fuels tumor growth.</li><li>ğŸ”— <a href=https://www.sciencedaily.com/releases/2025/12/251215025315.htm>æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>4.</strong> <strong>ç„¦è™‘å’Œå¤±çœ ä¸å…³é”®å…ç–«ç»†èƒæ•°é‡æ€¥å‰§ä¸‹é™æœ‰å…³</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmune</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šNatural killer cells act as the immune systemâ€™s rapid-response team, but the stress of anxiety and insomnia may be quietly thinning their ranks. A study of young women in Saudi Arabia found that both conditions were linked to significantly fewer NK cellsâ€”especially the circulating types responsible for destroying infected or abnormal cells. As anxiety severity increased, NK cell levels dropped even further, suggesting a stress-driven weakening of immune defenses.</li><li>ğŸ”— <a href=https://www.sciencedaily.com/releases/2025/12/251214100924.htm>æŸ¥çœ‹åŸæ–‡</a></li></ul></div></details><h2 id=-å…³é”®è¯ç»Ÿè®¡>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2><table><thead><tr><th>å…³é”®è¯</th><th>å‡ºç°æ¬¡æ•°</th></tr></thead><tbody><tr><td>cancer</td><td>18</td></tr><tr><td>RNA-seq</td><td>10</td></tr><tr><td>tumor</td><td>9</td></tr><tr><td>single-cell</td><td>9</td></tr><tr><td>ChIP-seq</td><td>7</td></tr><tr><td>immunity</td><td>7</td></tr><tr><td>sequencing</td><td>6</td></tr><tr><td>scRNA</td><td>5</td></tr><tr><td>immune</td><td>5</td></tr><tr><td>pathway</td><td>4</td></tr><tr><td>regex:onco(logy</td><td>logist</td></tr><tr><td>Neuronal</td><td>4</td></tr><tr><td>epigenetic</td><td>3</td></tr><tr><td>ATAC-seq</td><td>3</td></tr><tr><td>Alzheimer</td><td>3</td></tr><tr><td>metabolic</td><td>2</td></tr><tr><td>RNAseq</td><td>2</td></tr><tr><td>genome</td><td>1</td></tr><tr><td>spatially</td><td>1</td></tr><tr><td>KRAS</td><td>1</td></tr></tbody></table><hr><h2 id=-æ›´å¤šå†…å®¹>ğŸ“ æ›´å¤šå†…å®¹</h2><details><summary><a name=æ›´å¤š-æ•°æ®å‰æ²¿></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (58æ¡)</summary><div class=details-content markdown=1><ul><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293630">GSE293630 éœ¸æƒ EWSR1::ETS ç™ŒåŸºå› åœ¨å°¤æ–‡æ°è‚‰ç˜¤ä¸­å‡Œé©¾äºæ ¸å¿ƒè°ƒæ§å›è·¯æœºåˆ¶ä¹‹ä¸Š [ChIP-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293629">GSE293629 éœ¸æƒ EWSR1::ETS ç™ŒåŸºå› åœ¨å°¤æ–‡æ°è‚‰ç˜¤ä¸­å‡Œé©¾äºæ ¸å¿ƒè°ƒæ§å›è·¯æœºåˆ¶ä¹‹ä¸Š [RNA-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292538">GSE292538 KRASä¾èµ–æ€§å†…çš®ç»†èƒä»£è°¢é‡ç¼–ç¨‹ä½œä¸ºè„‘åŠ¨é™è„‰ç•¸å½¢çš„æ²»ç–—å¼±ç‚¹</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE255078">GSE255078 æ–­å¥¶åå–‚é£Ÿå«åŠä¹³ç³–ã€è‘¡è„ç³–æˆ–ä¹³ç³–é¥®é£Ÿçš„å°é¼ è¿‘ç«¯å°è‚ åˆ®å–ç‰©çš„ RNA æµ‹åº</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312888">GSE312888 è¡¨è§‚è½¬å½•ç»„ç¼–è¾‘ç­›é€‰é‰´å®šç™Œç—‡ä¸­çš„åŠŸèƒ½æ€§ m6A ä½ç‚¹ [RNA-Seq 22Rv1 M3 å†™å…¥]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300690">GSE300690 ç¥ç»å…ƒ Idol åŸºå› ç¼ºå¤±é€šè¿‡ APOE å—ä½“æ”¹å–„é˜¿å°”èŒ¨æµ·é»˜ç—…ç›¸å…³ç—…ç†</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298088">GSE298088 äººç±»åµå·¢é€æ˜ç»†èƒç™ŒPDXè‚¿ç˜¤çš„RNAæµ‹åº</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292092">GSE292092 é”™é…ä¿®å¤ç¼ºé™·é©±åŠ¨æ¶æ€§è¿›å±•å¹¶æ”¹å˜èƒ¶è´¨æ¯ç»†èƒç˜¤çš„è‚¿ç˜¤å…ç–«å¾®ç¯å¢ƒ</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE280897">GSE280897 PUF60ä»‹å¯¼çš„å‰ªæ¥æ˜¯ä¸‰é˜´æ€§ä¹³è…ºç™Œçš„å…³é”®é©±åŠ¨å› ç´ [RNA-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE261507">GSE261507 å…·æœ‰æ—¶é—´åˆ†è¾¨ç‡çš„æˆå¹´C57BL/6å°é¼ è˜æ£’çŠ¶ç»†èƒæŸä¼¤åè‚ºéƒ¨å…ç–«ç»†èƒçš„å•ç»†èƒè½¬å½•ç»„åˆ†æ</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE255794">GSE255794 è¡¨è§‚è½¬å½•ç»„ç¼–è¾‘ç­›é€‰é‰´å®šç™Œç—‡ä¸­çš„åŠŸèƒ½æ€§ m6A ä½ç‚¹ [ATAC-Seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE255792">GSE255792 è¡¨è§‚è½¬å½•ç»„ç¼–è¾‘ç­›é€‰é‰´å®šç™Œç—‡ä¸­çš„åŠŸèƒ½æ€§ m6A ä½ç‚¹ [ChIP-Seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313336">GSE313336 CALD1/IGF2BP1 å¤åˆç‰©é€šè¿‡ä»¥ mâ¶A ä¾èµ–çš„æ–¹å¼å¢å¼º RFC4 mRNA çš„ç¨³å®šæ€§æ¥ä»‹å¯¼è†€èƒ±ç™Œçš„é¡ºé“‚è€è¯æ€§ã€‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312993">GSE312993 FlncKO-C2C12 è‚Œæºæ€§åˆ†åŒ–è¿‡ç¨‹ä¸­çš„è½¬å½•ç»„åˆ†æï¼ˆæ‰¹é‡ RNA æµ‹åºï¼‰</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312903">GSE312903 Connectome-seqï¼šé€šè¿‡æ¡å½¢ç æµ‹åºæŠ€æœ¯ä»¥å•çªè§¦åˆ†è¾¨ç‡è¿›è¡Œé«˜é€šé‡ç¥ç»å…ƒè¿æ¥å›¾è°±ç»˜åˆ¶[snRNA-seq, ssRNA-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307955">GSE307955 H526å°ç»†èƒè‚ºç™Œç»†èƒä¸­PAX5çš„ChIP-seqåˆ†æ</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301438">GSE301438 TopBP1 é€šè¿‡ PU.1 å’Œ IRF8 æ§åˆ¶ä¼ ç»Ÿæ ‘çªçŠ¶ç»†èƒå‘è‚²å’Œ Flt3L é©±åŠ¨çš„ cDC1 åˆ†åŒ– [ChIP-Seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE271510">GSE271510 å°é¼ KPCèƒ°è…ºè‚¿ç˜¤çš„å•ç»†èƒRNAæµ‹åº</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE271509">GSE271509 å°é¼ KPCèƒ°è…ºè‚¿ç˜¤çš„å•ç»†èƒATACæµ‹åº</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312168">GSE312168 ç»„ç»‡æŸä¼¤ç ”ç©¶ä¸­è½¬å½•ç»„å’Œä»£è°¢ç»„å˜åŒ–çš„ç©ºé—´åˆ†è¾¨æ•´åˆåˆ†æ</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298302">GSE298302 è¥¿è¾¾ç±³å¾·å’Œå¡åˆ©å°¼ç´¢é€šè¿‡æŠ‘åˆ¶ Survivin å’Œ PI3K/AKT é€šè·¯ï¼Œåœ¨é«˜çº§åˆ« B ç»†èƒæ·‹å·´ç˜¤ä¸­å‘æŒ¥åŒé‡è¡¨è§‚é—ä¼ å’Œæ ¸è¾“å‡ºæŠ‘åˆ¶ä½œç”¨</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE286170">GSE286170 GABAèƒ½ç¥ç»å…ƒåœ¨é©±åŠ¨è„†æ€§XæŸ“è‰²ä½“å‰çªå˜æºå¸¦è€…ç›¸å…³çš„CGGé‡å¤æ¯’æ€§ä¸­èµ·å…³é”®ä½œç”¨[scRNA-Seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE256000">GSE256000 åŸå‘æ€§è‚¾å°ç®¡å’Œé€æ˜ç»†èƒè‚¾ç»†èƒç™Œç»†èƒä¸­å¼€æ”¾æŸ“è‰²è´¨ã€HIF ç»“åˆå’Œ mRNA è¡¨è¾¾åˆ†æ [RNA-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE255998">GSE255998 åŸå‘æ€§è‚¾å°ç®¡å’Œ ccRCC ç»†èƒä¸­çš„å¼€æ”¾æŸ“è‰²è´¨ã€HIF ç»“åˆå’Œ mRNA è¡¨è¾¾åˆ†æ [ATAC-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE255997">GSE255997 åŸå‘æ€§è‚¾å°ç®¡å’Œ ccRCC ç»†èƒä¸­å¼€æ”¾æŸ“è‰²è´¨ã€HIF ç»“åˆå’Œ mRNA è¡¨è¾¾åˆ†æ [ChIP-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313775">GSE313775 å­å®«å†…è†œå¼‚ä½ç—‡æ‚£è€…å’Œå¯¹ç…§ç»„çš„å¾ªç¯ Th1ã€Th1/17 å’Œ Th17 ç»†èƒ RNA æµ‹åº</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313636">GSE313636 å¯¹æœªæ„ŸæŸ“æˆ–å‡ç»“æ ¸è€¶å°”æ£®èŒæ„ŸæŸ“çš„å›è‚ è¿›è¡Œç©ºé—´è½¬å½•ç»„åˆ†æï¼Œæ­ç¤ºäº†ä¸€ç§æ–°çš„è‚ ç»†èƒè½¬å½•çŠ¶æ€</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313324">GSE313324 PUF60ä»‹å¯¼çš„å‰ªæ¥æ˜¯ä¸‰é˜´æ€§ä¹³è…ºç™Œçš„å…³é”®é©±åŠ¨å› ç´ [CRISPR]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313289">GSE313289 é€šè¿‡åŸºå› è¡¨è¾¾äº†è§£å¤´é¢ˆéƒ¨é³çŠ¶ç»†èƒç™Œçš„è‚¿ç˜¤å¼‚è´¨æ€§</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313117">GSE313117 åŸºäºåŸºå› è¡¨è¾¾çš„ç™Œç—‡åˆ†å­åˆ†å‹è·¨å¹³å°æ¯”è¾ƒæ­ç¤ºäº†ä¸å¤–æ˜¾å­æ•è·æ–¹æ³•çš„å·®å¼‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312890">GSE312890 è¡¨è§‚è½¬å½•ç»„ç¼–è¾‘ç­›é€‰é‰´å®šç™Œç—‡ä¸­çš„åŠŸèƒ½æ€§ m6A ä½ç‚¹ [CRISPR screen_H358]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309818">GSE309818 ç¥ç»åµ´ç»†èƒè¡ç”Ÿçš„ DKK1 è°ƒèŠ‚ç¬¬äºŒå¿ƒåœºä¸­çš„ Wnt ä¿¡å·ä¼ å¯¼ï¼Œä»è€Œåè°ƒå¿ƒè„æµå‡ºé“å‘è‚²ã€‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305625">GSE305625 ä¾›ä½“åŒ¹é…è¡€æµ†å’Œè„‘è„Šæ¶²ä¸­å¤šmiRNAæ¨¡å‹ä½œä¸ºé˜¿å°”èŒ¨æµ·é»˜ç—…é¢„æµ‹å€™é€‰ç”Ÿç‰©æ ‡å¿—ç‰©çš„æ¯”è¾ƒ</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297746">GSE297746 è‡ªç”±æ¼‚æµ®çš„é•¿æœŸè¡€ç®¡åŒ–é—´å……è´¨ç±»å™¨å®˜ [RNA-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297680">GSE297680 è‡ªç”±æ¼‚æµ®çš„é•¿æœŸè¡€ç®¡åŒ–é—´å……è´¨ç±»å™¨å®˜ [scRNA-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE295765">GSE295765 ç¯çŠ¶ ZBTB44 ç¼–ç çš„ ZBTB44-342aa é€šè¿‡æŠ‘åˆ¶ cGAS-STING é€šè·¯å‡è½»äººä¸»åŠ¨è„‰ç“£é—´è´¨ç»†èƒçš„æˆéª¨åˆ†åŒ–</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE280899">GSE280899 PUF60ä»‹å¯¼çš„å‰ªæ¥æ˜¯ä¸‰é˜´æ€§ä¹³è…ºç™Œçš„å…³é”®é©±åŠ¨å› ç´ </a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE280898">GSE280898 PUF60ä»‹å¯¼çš„å‰ªæ¥æ˜¯ä¸‰é˜´æ€§ä¹³è…ºç™Œçš„å…³é”®é©±åŠ¨å› ç´ [eCLIP]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE268609">GSE268609 äººç±»æµ·é©¬ç¥ç»å‘ç”Ÿä¸æˆå¹´ã€è¡°è€å’Œé˜¿å°”èŒ¨æµ·é»˜ç—…çš„å…³ç³»è·¯çº¿å›¾</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE243490">GSE243490 äººç±»å—œé…¸æ€§ç²’ç»†èƒ1å‹å’Œ2å‹çš„å…ç–«æåŒ–</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE243369">GSE243369 å°é¼ å—œé…¸æ€§ç²’ç»†èƒ1å‹å’Œ2å‹çš„å…ç–«æåŒ–</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE242447">GSE242447 è¡¨è§‚è½¬å½•ç»„ç¼–è¾‘ç­›é€‰é‰´å®šå‡ºç™Œç—‡ä¸­çš„åŠŸèƒ½æ€§ m6A ä½ç‚¹</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE242446">GSE242446 è¡¨è§‚è½¬å½•ç»„ç¼–è¾‘ç­›é€‰é‰´å®šç™Œç—‡ä¸­çš„åŠŸèƒ½æ€§ m6A ä½ç‚¹ [CRISPR screen_22Rv1]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE242444">GSE242444 è¡¨è§‚è½¬å½•ç»„ç¼–è¾‘ç­›é€‰é‰´å®šç™Œç—‡ä¸­çš„åŠŸèƒ½æ€§ m6A ä½ç‚¹ [RNA-Seq_shKD]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313838">GSE313838 é›„æ¿€ç´ å—ä½“é˜´æ€§å‰åˆ—è…ºç™Œæ˜“å—SWI/SNFé¶å‘é™è§£åˆ†å­çš„å½±å“</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313525">GSE313525 TAK1 æ˜¯æ¨ªçº¹è‚Œè‚‰ç˜¤ä¸­è‡´ç™Œä¿¡å·ä¼ å¯¼å’Œåˆ†åŒ–é˜»æ»çš„å…³é”®è°ƒèŠ‚å› å­</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313497">GSE313497 æ€¥æ€§ç¡çœ å‰¥å¤ºå¯¹å°é¼ æµ·é©¬å’Œå‰é¢å¶çš®å±‚éç¥ç»å…ƒç»†èƒè½¬å½•ç»„ç‰¹å¾çš„ç»†èƒç‰¹å¼‚æ€§å½±å“</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313438">GSE313438 æ·«ç¾Šè—¿è‹·é€šè¿‡ä¿ƒè¿›TFEBä¾èµ–æ€§çº¿ç²’ä½“æ¸…é™¤å’Œä»£è°¢é‡ç¼–ç¨‹æ¥ç¼“è§£è¿åŠ¨å¼•èµ·çš„ç–²åŠ³</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313307">GSE313307 ç³»ç»Ÿæ€§æ„ŸæŸ“æ”¹å˜é˜¿å°”èŒ¨æµ·é»˜ç—…æ‚£è€…çš„çš®è´¨è½¬å½•ç‰¹å¾</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312982">GSE312982 äººç±»éª¨é«“è„‚è‚ªç»†èƒé€šè¿‡è„‚è´¨ä»‹å¯¼çš„è¡€ç®¡ç”Ÿæˆç´ æ ·è›‹ç™½4è¯±å¯¼ä¿ƒè¿›å‰åˆ—è…ºç™Œéª¨è½¬ç§»è¿›å±•</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308383">GSE308383 å°é¼ è‚ ç¥ç»ç³»ç»Ÿçš„å•æ ¸è½¬å½•ç»„åˆ†æ</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307220">GSE307220 Dgat1 é€šè¿‡è§£æ¯’é›„æ¿€ç´ å—ä½“ä¿¡å·é€šè·¯ä¿ƒè¿›æŠ—è‚¿ç˜¤ CD8+ T ç»†èƒååº”</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301451">GSE301451 ç¥ç»å…ƒå¶åƒç¼ºå¤±å¯æ”¹å–„æ·€ç²‰æ ·è›‹ç™½ç—…ç†</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296719">GSE296719 é“‚(II)é…åˆç‰©æŠ‘åˆ¶ç™Œå¹²ç»†èƒè‡ªæˆ‘æ›´æ–°å¯æŠ‘åˆ¶èƒƒè‚ é“ç™Œè½¬ç§»</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE295408">GSE295408 é¶å‘è¡€æ¸…ç´ é©±åŠ¨çš„ç»„è›‹ç™½è¡€æ¸…ç´ åŒ–å¯æŠ‘åˆ¶NEPCçš„è°±ç³»å¯å¡‘æ€§å’Œè¿›å±•</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289577">GSE289577 NR5A2 çš„å‰é¦ˆè°ƒæ§ç¯è·¯ç¡®ä¿æ¤å…¥å‰å‘è‚²è¿‡ç¨‹ä¸­åŸºå› çš„ç¨³å¥æ¿€æ´» [RNA-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289573">GSE289573 NR5A2 çš„å‰é¦ˆè°ƒæ§ç¯è·¯ç¡®ä¿æ¤å…¥å‰å‘è‚²è¿‡ç¨‹ä¸­åŸºå› çš„ç¨³å¥æ¿€æ´» [ATAC-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE124850">GSE124850 ç¯çŠ¶RNAåœ¨è‚ç»†èƒç™Œè‚¿ç˜¤åŠè‚¿ç˜¤å‘¨å›´ç»„ç»‡ä¸­çš„è¡¨è¾¾åˆ†æ</a></li></ul></div></details><hr><p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2025-12-16 21:39</em><br><em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p></div><footer class=post__footer><div class="post__tags tags clearfix"><svg class="tags__badge icon icon-tag" width="16" height="16" viewBox="0 0 32 32"><path d="M4 0h8s2 0 4 2l15 15s2 2 0 4L21 31s-2 2-4 0L2 16s-2-2-2-4V3s0-3 4-3m3 10a3 3 0 000-6 3 3 0 000 6"/></svg><ul class=tags__list><li class=tags__item><a class="tags__link btn" href=../../../tags/research/ rel=tag>Research</a></li><li class=tags__item><a class="tags__link btn" href=../../../tags/daily/ rel=tag>Daily</a></li><li class=tags__item><a class="tags__link btn" href=../../../tags/week512025/ rel=tag>Week512025</a></li></ul></div></footer></article></main><div class="authorbox clearfix"><div class=authorbox__header><span class=authorbox__name>About Bloger</span></div></div><nav class="pager flex"><div class="pager__item pager__item--prev"><a class=pager__link href=../../../posts/dailyreports/2025-12-16/ rel=prev><span class=pager__subtitle>Â«&#8201;Previous</span><p class=pager__title>ç§‘ç ”æ—¥æŠ¥ 2025-12-16</p></a></div><div class="pager__item pager__item--next"><a class=pager__link href=../../../posts/dailyreports/2025-12-18/ rel=next><span class=pager__subtitle>Next&#8201;Â»</span><p class=pager__title>ç§‘ç ”æ—¥æŠ¥ 2025-12-18</p></a></div></nav><section class=comments><div id=disqus_thread></div><script>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//kkitown.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></section></div><aside class=sidebar><div class="widget-search widget"><form class=widget-search__form role=search method=get action=https://google.com/search><input class=widget-search__field type=search placeholder=Searchâ€¦ name=q aria-label=Searchâ€¦>
<input class=widget-search__submit type=submit value=Search>
<input type=hidden name=sitesearch value=https://ixxmu.github.io/></form></div><div class="widget-recent widget"><h4 class=widget__title>Recent Posts</h4><div class=widget__content><ul class=widget__list><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-02-16/>ç§‘ç ”æ—¥æŠ¥ 2026-02-16</a></li><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-02-15/>ç§‘ç ”æ—¥æŠ¥ 2026-02-15</a></li><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-02-14/>ç§‘ç ”æ—¥æŠ¥ 2026-02-14</a></li><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-02-13/>ç§‘ç ”æ—¥æŠ¥ 2026-02-13</a></li><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-02-12/>ç§‘ç ”æ—¥æŠ¥ 2026-02-12</a></li></ul></div></div><div class="widget-categories widget"><h4 class=widget__title>Categories</h4><div class=widget__content><ul class=widget__list><li class=widget__item><a class=widget__link href=../../../categories/dailyreport/>DailyReport</a></li><li class=widget__item><a class=widget__link href=../../../categories/learnr/>LearnR</a></li></ul></div></div><div class="widget-taglist widget"><h4 class=widget__title>Tags</h4><div class=widget__content><a class="widget-taglist__link widget__link btn" href=../../../tags/daily/ title=Daily>Daily (109)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/research/ title=Research>Research (109)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week022026/ title=Week022026>Week022026 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week032026/ title=Week032026>Week032026 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week042026/ title=Week042026>Week042026 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week052026/ title=Week052026>Week052026 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week062026/ title=Week062026>Week062026 (6)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week072026/ title=Week072026>Week072026 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week452025/ title=Week452025>Week452025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week462025/ title=Week462025>Week462025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week472025/ title=Week472025>Week472025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week482025/ title=Week482025>Week482025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week492025/ title=Week492025>Week492025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week502025/ title=Week502025>Week502025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week512025/ title=Week512025>Week512025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week522025/ title=Week522025>Week522025 (7)</a></div><a href=../../../tags/></a></div><div class="widget-social widget"><h4 class="widget-social__title widget__title">Social</h4><div class="widget-social__content widget__content"><div class="widget-social__item widget__item"><a class="widget-social__link widget__link btn" title=Facebook rel="noopener noreferrer" href=https://facebook.com/username target=_blank><svg class="widget-social__link-icon icon icon-facebook" width="24" height="24" viewBox="0 0 352 352"><path d="m0 32v288c0 17.5 14.5 32 32 32h288c17.5.0 32-14.5 32-32V32c0-17.5-14.5-32-32-32H32C14.5.0.0 14.5.0 32zm320 0v288h-83V212h41.5l6-48H237v-31c0-14 3.5-23.5 23.5-23.5h26V66c-4.4-.6-19.8-1.5-37.5-1.5-36.9.0-62 22.2-62 63.5v36h-42v48h42v108H32V32z"/></svg>
<span>Facebook</span></a></div><div class="widget-social__item widget__item"><a class="widget-social__link widget__link btn" title=Twitter rel="noopener noreferrer" href=https://twitter.com/username target=_blank><svg class="widget-social__link-icon icon icon-twitter" width="24" height="24" viewBox="0 0 384 312"><path d="m384 36.9c-14.1 6.3-29.3 10.5-45.2 12.4 16.3-9.7 28.8-25.2 34.6-43.6-15.2 9-32.1 15.6-50 19.1-14.4-15.2-34.9-24.8-57.5-24.8-43.5.0-78.8 35.3-78.8 78.8.0 6.2.7 12.2 2 17.9-65.5-3.3-123.5-34.6-162.4-82.3C20 26 16.1 39.6 16.1 54c0 27.3 13.9 51.4 35 65.6-12.9-.4-25.1-4-35.7-9.9v1c0 38.2 27.2 70 63.2 77.2-6.6 1.8-13.6 2.8-20.8 2.8-5.1.0-10-.5-14.8-1.4 10 31.3 39.1 54.1 73.6 54.7-27 21.1-60.9 33.7-97.8 33.7-6.4.0-12.6-.4-18.8-1.1C34.9 299 76.3 312 120.8 312c144.9.0 224.1-120 224.1-224.1.0-3.4-.1-6.8-.2-10.2 15.4-11.1 28.7-25 39.3-40.8z"/></svg>
<span>Twitter</span></a></div><div class="widget-social__item widget__item"><a class="widget-social__link widget__link btn" title=Instagram rel="noopener noreferrer" href=https://www.instagram.com/username target=_blank><svg class="widget-social__link-icon icon icon-instagram" width="24" height="24" viewBox="0 0 256 256"><circle cx="193" cy="59" r="15"/><path fill-rule="evenodd" d="M101 0h54c41 0 58.4 3.9 74.5 17C256.2 37.5 256 74.8 256 97.7v60c0 26.7.0 60.4-26.5 81.4-16 13.4-33.5 16.9-74.5 16.9h-54c-41 0-57.5-3.5-74.5-16.9C1 218.9.5 186.3.1 160.5L0 155V97.7c0-23-.2-60.2 26.5-80.7C45 2 60 0 101 0zm4.9 23h44.3c45.8.0 58.3 3.5 70.3 17.5 11.8 13.2 12 30.1 12.5 62.9V156c.2 20.8.3 45.8-12.5 59.5-12 14-24.5 17.5-70.3 17.5h-44.3c-45.9.0-57.3-3.5-70.4-17.5-12.2-13-12.3-36.5-12.4-56.7v-55.6c.4-32.6.7-49.6 12.4-62.7C48 26.5 60 23 105.9 23zm19.6 144.5a42 42 0 100-84 42 42 0 000 84zm0 22.5a64.5 64.5.0 100-129 64.5 64.5.0 000 129z"/></svg>
<span>Instagram</span></a></div></div></div></aside></div><footer class=footer><div class="container footer__container flex"><div class=footer__copyright>&copy; 2026 ç”Ÿä¿¡æ™®æ‹‰æ–¯.
<span class=footer__copyright-credits>Generated with <a href=https://gohugo.io/ rel="nofollow noopener" target=_blank>Hugo</a> and <a href=https://github.com/Vimux/Mainroad/ rel="nofollow noopener" target=_blank>Mainroad</a> theme.</span></div></div></footer></div><script async defer src=../../../js/menu.js></script><script src=../../../js/custom.js></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.6/MathJax.js?config=TeX-AMS-MML_HTMLorMML" async></script></body></html>